Currently, there are 806.68M common shares owned by the public and among those 377.26M shares have been available to trade.
The company’s stock has a 5-day price change of 12.29% and 5.83% over the past three months. ROIV shares are trading 13.09% year to date (YTD), with the 12-month market performance up to 39.56% higher. It has a 12-month low price of $8.61 and touched a high of $13.06 over the same period. ROIV has an average intraday trading volume of 6.23 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.95%, 8.40%, and 12.97% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Roivant Sciences Ltd (NASDAQ: ROIV) shares accounts for 67.69% of the company’s 806.68M shares outstanding.
It has a market capitalization of $9.24B and a beta (3y monthly) value of 1.25. The stock’s trailing 12-month PE ratio is 2.25, while the earnings-per-share (ttm) stands at $5.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.86% over the week and 2.97% over the month.
Earnings per share for the fiscal year are expected to decrease by -113.38%, and -47.94% over the next financial year.
Looking at the support for the ROIV, a number of firms have released research notes about the stock. Wolfe Research stated their Outperform rating for the stock in a research note on February 15, 2024, with the firm’s price target at $17. Piper Sandler coverage for the Roivant Sciences Ltd (ROIV) stock in a research note released on January 05, 2024 offered a Overweight rating with a price target of $20. Deutsche Bank was of a view on December 12, 2023 that the stock is Buy, while Guggenheim gave the stock Buy rating on October 17, 2023, issuing a price target of $17. BofA Securities on their part issued Neutral rating on June 08, 2023.
